MedTrace Logo

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

NCT04445246 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-29

No results posted yet for this study

Summary

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

Conditions

  • COVID-19
  • ARDS, Human
  • Hypoxemic Respiratory Failure

Interventions

DRUG

Inhaled ILOPROST

Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.

Sponsors & Collaborators

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Nadir Kharma, MD · Hamad Medical Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-23
Primary Completion
2021-05-31
Completion
2021-05-31
FDA Drug
Yes

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04445246 on ClinicalTrials.gov